Market Research > Industries > Chemicals

Market Research: Specialty Excipients for Oral
Solid-Dosage-Form Pharmaceuticals 2008:
Europe Market Analysis and Opportunities

Specialty Excipients for Oral Solid-Dosage-Form Pharmaceuticals 2008: Europe Market Analysis and Opportunities

Published September 2008

View PDF brochure

This report provides a comprehensive examination of the complex and fragmented global market for oral solid-dosage products. Each regional volume features distinct and detailed analyses of five major specialty excipient categories and more than 25 individual products. Key industry dynamics and trends are also examined in each volume. Detailed assessments of specialty excipient procurement practices and business profiles of leading and niche specialty excipient and delivery technology suppliers are provided for each region. A forecast to 2015 completes each regional volume. (Y611D.01)

	ORDER ONLINE

You may submit an online request to subscribe to sections of this report, using a simple three-step process. After submitting your online request, you will then be contacted by a member of our global sales team to confirm the final price, and complete the transaction. Upon acceptance of your order, we will deliver the files in pdf format via email.

STEP 1 of 3

– Select the sections in which you are interested by clicking on the appropriate boxes:

Full Report [US$ 31 250 (thirty one thousand two hundred fifty US Dollars)]

Introduction [US$ 0]

Table 1-1 SELECTED SPECIALTY EXCIPIENTS COVERED IN THIS STUDY BY PRODUCT CLASS
Table 1-2 COMMON ABBREVIATIONS AND ACRONYMS USED IN THIS REPORT

Pharmaceutical Industry Overview [US$ 3 800]

The Global Market [US$ 2 100]

Table 3-1 GLOBAL MANUFACTURERS’ SALES OF PHARMACEUTICALS BY REGION, 2007
Table 3-2 TOP 10 PHARMACEUTICAL PRODUCTS BY GLOBAL MANUFACTURERS’ SALES, 2007
Table 3-3 TOP 10 THERAPY CLASSES BY GLOBAL MANUFACTURERS’ SALES, 2007
Table 3-4 HEALTH-CARE REVENUES AND RESEARCH AND DEVELOPMENT EXPENDITURES FOR LEADING GLOBAL PHARMACEUTICAL/BIOTECHNOLOGY COMPANIES, 2006

The European Market [US$ 2 100]

Table 3-5 KEY DATA FOR THE EUROPEAN PHARMACEUTICAL MARKET, 1990 TO 2006
Table 3-6 GLOBAL VACCINE-INDUSTRY SALES BY REGION, 2006<
Table 3-7 MARKET SHARE OF GENERIC DRUGS IN EUROPE BY COUNTRY, 2005
Table 3-8 LIST OF SELECTED DRUG PATENT EXPIRATIONS, 2007 TO 2009
Table 3-9 VALUE ADDED TAX RATES APPLICABLE TO MEDICINES IN EUROPE, 2007
Table 3-10 KEY DATA FOR THE BIOPHARMACEUTICAL SECTOR IN THE UNITED STATES AND EUROPE, 2006

Specialty Binders and Fillers [US$ 9 400]

Table 4-1 ESTIMATED CONSUMPTION OF SPECIALTY BINDERS AND FILLERS IN EUROPE BY PRODUCT CLASS AND TYPE, 2007
Table 4-2 SUPPLIERS OF SPECIALTY BINDERS AND FILLERS TO THE OSDF PHARMACEUTICAL MARKET IN EUROPE, 2007
Table 4-3 ESTIMATED VOLUME SALES OF SPECIALTY BINDERS AND FILLERS FOR OSDF PHARMACEUTICAL APPLICATIONS IN EUROPE BY SUPPLIER AND PRODUCT CLASS, 2007
Table 4-4 ESTIMATED VALUE SALES OF SPECIALTY BINDERS AND FILLERS FOR OSDF PHARMACEUTICAL APPLICATIONS IN EUROPE BY SUPPLIER AND PRODUCT CLASS, 2007
Table 4-5 FORECAST CONSUMPTION OF SPECIALTY BINDERS AND FILLERS FOR OSDF PHARMACEUTICAL APPLICATIONS IN EUROPE BY PRODUCT CLASS AND TYPE, 2007 TO 2012

Alginates [US$ 900]

Table 4A-1 ESTIMATED SALES OF ALGINATES FOR OSDF PHARMACEUTICAL APPLICATIONS IN EUROPE BY SUPPLIER, 2007

Cellulosics [US$ 3 000]

Table 4B-1 ESTIMATED SALES OF CELLULOSICS FOR OSDF PHARMACEUTICAL APPLICATIONS IN EUROPE BY PRODUCT TYPE, 2007

Table 4B-2 ESTIMATED SALES VOLUME OF CELLULOSICS FOR OSDF PHARMACEUTICAL APPLICATIONS IN EUROPE BY SUPPLIER AND PRODUCT TYPE, 2007

Table 4B-3 ESTIMATED SALES VALUE OF CELLULOSICS FOR OSDF PHARMACEUTICAL APPLICATIONS IN EUROPE BY SUPPLIER AND PRODUCT TYPE, 2007

Table 4B-4 FORECAST SALES OF CELLULOSICS FOR OSDF PHARMACEUTICAL APPLICATIONS IN EUROPE BY SUPPLIER, 2007 TO 2012

Carboxymethylcellulose sodium [US$ 900]

Table 4B-5 ESTIMATED SALES OF CMC FOR OSDF PHARMACEUTICAL APPLICATIONS IN EUROPE BY SUPPLIER, 2007

Ethyl cellulose [US$ 900]

Table 4B-6 SELECTED GRADES OF EC (DRY) BY SUPPLIER, 2007

Table 4B-7 ESTIMATED SALES OF EC FOR OSDF PHARMACEUTICAL APPLICATIONS IN EUROPE BY SUPPLIER, 2007

Hydroxypropyl cellulose [US$ 600]

Table 4B-8 ESTIMATED SALES OF HPC FOR OSDF PHARMACEUTICAL APPLICATIONS IN EUROPE BY SUPPLIER, 2007

Hydroxypropyl methylcellulose [US$ 900]

Table 4B-9 ESTIMATED SALES OF HPMC FOR OSDF PHARMACEUTICAL APPLICATIONS IN EUROPE BY SUPPLIER, 2007

Microcrystalline Cellulose [US$ 900]

Table 4B-10 LIST OF SELECTED GRADES OF MCC IN EUROPE BY SUPPLIER AND PARTICLE SIZE

Table 4B-11 LIST OF SELECTED MCC PRODUCTS FROM FMC BIOPOLYMER

Table 4B-12 ESTIMATED SALES OF MCC FOR OSDF PHARMACEUTICAL APPLICATIONS IN EUROPE BY SUPPLIER, 2007

Table 4B-13 LIST OF SELECTED MCC PRODUCTS SUPPLIED BY JRS PHARMA

Table 4B-14 LIST OF SELECTED MCC PRODUCTS FROM MING-TAI

Table 4B-15 LIST OF SELECTED MCC PRODUCTS FROM BLANVER

Calcium Phosphates [US$ 900]

Table 4C-1 ESTIMATED SALES OF CALCIUM PHOSPHATES FOR OSDF PHARMACEUTICAL APPLICATIONS IN EUROPE BY SUPPLIER, 2007

Directly Compressible Sucrose [US$ 900]

Table 4D-1 ESTIMATED SALES OF DIRECTLY COMPRESSIBLE SUCROSE FOR OSDF PHARMACEUTICAL APPLICATIONS IN EUROPE BY SUPPLIER, 2007

Lactose [US$ 900]

Table 4E-1 ESTIMATED SALES OF LACTOSE FOR OSDF PHARMACEUTICAL APPLICATIONS IN EUROPE BY SUPPLIER, 2007

Polyols [US$ 1 600]

Table 4F-1 ESTIMATED SALES OF POLYOLS FOR OSDF PHARMACEUTICAL APPLICATIONS IN EUROPE BY SUPPLIER, 2007

Mannitol [US$ 900]

Table 4F-2 ESTIMATED SALES OF MANNITOL FOR OSDF PHARMACEUTICAL APPLICATIONS IN EUROPE BY SUPPLIER, 2007

Sorbitol [US$ 900]

Table 4F-3 ESTIMATED SALES OF SORBITOL FOR OSDF PHARMACEUTICAL APPLICATIONS IN EUROPE BY SUPPLIER, 2007

Providone [US$ 900]

Table 4G-1 ESTIMATED SALES OF POVIDONE FOR OSDF PHARMACEUTICAL APPLICATIONS IN EUROPE BY SUPPLIER, 2007

Starches [US$ 900]

Table 4H-1 TRADE NAMES OF SELECTED STARCH PRODUCTS IN EUROPE BY SUPPLIER

Table 4H-2 ESTIMATED SALES OF STARCHES FOR OSDF PHARMACEUTICAL APPLICATIONS IN EUROPE BY SUPPLIER AND PRODUCT TYPE, 2007

Xanthan Gum [US$ 900]

Table 4I-1 ESTIMATED SALES OF XANTHAN GUM FOR OSDF PHARMACEUTICAL APPLICATIONS IN EUROPE BY SUPPLIER, 2007

Disintegrants [US$ 3 800]

Table 5-1 ESTIMATED CONSUMPTION OF DISINTEGRANTS FOR OSDF PHARMACEUTICAL APPLICATIONS IN EUROPE BY PRODUCT TYPE, 2007

Table 5-2 ESTIMATED CONSUMPTION OF DISINTEGRANTS FOR OSDF PHARMACEUTICAL APPLICATIONS IN EUROPE BY SUPPLIER, 2007

Table 5-3 FORECAST CONSUMPTION OF DISINTEGRANTS FOR OSDF PHARMACEUTICAL APPLICATIONS IN EUROPE BY PRODUCT TYPE, 2007 TO 2012

Crospovidone [US$ 1 500]

Table 5A-1 SELECT LIST OF ORALLY DISINTEGRATING TABLET PRODUCTS PRODUCED IN THE UNITED STATES AND EUROPE

Table 5A-2 ESTIMATED SALES OF CROSPOVIDONE FOR OSDF PHARMACEUTICAL APPLICATIONS IN EUROPE BY SUPPLIER, 2007

Croscarmellose Sodium [US$ 1 500]

Table 5B-1 ESTIMATED SALES OF CROSCARMELLOSE SODIUM FOR OSDF PHARMACEUTICAL APPLICATIONS IN EUROPE BY SUPPLIER, 2007

Sodium Starch Glycolate [US$ 1 500]

Table 5C-1 ESTIMATED SALES OF SODIUM STARCH GLYCOLATE FOR OSDF PHARMACEUTICAL APPLICATIONS IN EUROPE BY SUPPLIER, 2007

Lubricants: Magnesium stearate [US$ 3 100]

Table 6-1 ESTIMATED SALES OF MAGNESIUM STEARATE FOR OSDF PHARMACEUTICAL APPLICATIONS IN EUROPE BY SUPPLIER, 2007

Coatings [US$ 4 700]

Table 7-1 LIST OF SELECTED POLYMER FILM FORMERS USED IN COATINGS FOR OSDF APPLICATIONS, 2007
Table 7-2 LIST OF SELECTED FORMULATED COLOR COATINGS FOR OSDF APPLICATIONS, 2007
Table 7-3 ESTIMATED CONSUMPTION BY VALUE OF FORMULATED COATINGS AND POLYMERS USED IN OSDF APPLICATIONS IN EUROPE BY PRODUCT TYPE, 2007
Table 7-4 ESTIMATED CONSUMPTION BY VOLUME OF POLYMERS USED IN OSDF APPLICATIONS IN EUROPE BY PRODUCT TYPE, 2007
Table 7-5 ESTIMATED SALES OF PHARMACEUTICAL AND FORMULATED COATINGS IN EUROPE BY PRODUCT SEGMENT AND SUPPLIER, 2007
Table 7-6 FORECAST CONSUMPTION OF FORMULATED COATINGS AND FILM FORMERS IN PHARMACEUTICAL COATINGS IN EUROPE BY PRODUCT SEGMENT AND TYPE, 2007 TO 2012

Polymers/Film Formers [US$ 3 100]

Table 7A-1 SELECTED LIST OF COMMERCIAL POLYMERS FOR COATING APPLICATIONS, 2007

Table 7A-2 TABLET FUNCTIONS OF POLYMERS USED AS FILM FORMERS BY TYPE

Table 7A-3 SELECTED LIST OF POLYMERS USED AS FILM FORMERS IN EUROPE BY PRODUCT

Table 7A-4 PRICING OF POLYMERS USED IN COATINGS IN EUROPE, 2007

Table 7A-5 ESTIMATED CONSUMPTION BY VOLUME OF POLYMERS USED IN PHARMACEUTICAL COATINGS IN EUROPE BY PRODUCT SEGMENT AND TYPE, 2007

Table 7A-6 ESTIMATED CONSUMPTION OF POLYMERS USED IN PHARMACEUTICAL COATINGS IN EUROPE BY SUPPLIER, 2007

Table 7A-7 FORECAST CONSUMPTION OF POLYMERS IN PHARMACEUTICAL COATINGS IN EUROPE BY PRODUCT TYPE, 2007 TO 2012
Hydroxypropyl methylcellulose [US$ 900]

Table 7A-8 ESTIMATED CONSUMPTION BY VALUE OF HPMC USED IN PHARMACEUTICAL COATINGS IN EUROPE BY PRODUCT TYPE, 2007

Table 7A-9 ESTIMATED CONSUMPTION BY VALUE OF HPMC USED IN PHARMACEUTICAL COATINGS IN EUROPE BY SUPPLIER, 2007

Polymethacrylates [US$ 900]

Table 7A-10 SELECTED COMMERCIAL POLYMETHACRYLATES FOR COATING APPLICATIONS, 2007

Table 7A-11 ESTIMATED CONSUMPTION OF POLYMETHACRYLATES USED IN PHARMACEUTICAL COATINGS IN EUROPE BY PRODUCT TYPE, 2007

Table 7A-12 ESTIMATED CONSUMPTION OF POLYMETHACRYLATES USED IN PHARMACEUTICAL COATINGS IN EUROPE BY PRODUCT TYPE, 2007

Cellulose acetate phthalate [US$ 900]

Ethyl cellulose [US$ 900]

Table 7A-13 ESTIMATED CONSUMPTION OF ETHYL CELLULOSE USED IN PHARMACEUTICAL COATINGS IN EUROPE BY PRODUCT TYPE, 2007

Table 7A-14 ESTIMATED CONSUMPTION OF ETHYL CELLULOSE USED IN PHARMACEUTICAL COATINGS IN EUROPE BY SUPPLIER, 2007

Formulated Coatings [US$ 700]

Table 7B-1 LIST OF SELECTED FORMULATED COLOR COATINGS FOR OSDF APPLICATIONS, 2007
Table 7B-2 ESTIMATED CONSUMPTION OF FORMULATED PHARMACEUTICAL COATINGS IN EUROPE BY PRODUCT TYPE, 2007
Table 7B-3 ESTIMATED SALES OF FORMULATED PHARMACEUTICAL COATINGS IN EUROPE BY SUPPLIER, 2007
Table 7B-4 FORECAST CONSUMPTION OF FORMULATED PHARMACEUTICAL COATINGS IN EUROPE BY PRODUCT TYPE, 2007 TO 2012

Coating Types [US$ 700]

Table 7C-1 FUNCTIONALITIES OF SELECTED POLYMERS FOR OSDF COATINGS APPLICATIONS, 2007
Table 7C-2 LIST OF SELECTED PRODUCTS FOR FILM COATING APPLICATIONS
Figure 7C-1 FACTORS INFLUENCING THE SUGAR COATING PROCESS
Figure 7C-2 LAYERING COMBINATIONS FOR SUGAR COATING APPLICATIONS
Figure 7C-3 SELECTED RAW MATERIALS FOR SUGAR COATINGS BY COATING CATEGORY

Coating Functions [US$ 900]

Aesthetic/Finishing Coatings [US$ 300]

Protective Coatings [US$ 300]

Enteric/Delayed Coatings [US$ 300]

Table 7D-1 LIST OF SELECTED ENTERIC COATING POLYMERS, 2007

Sustained-Release Coatings [US$ 300]

Table 7D-2 LIST OF SELECTED PRODUCTS USED IN SUSTAINED-RELEASE COATINGS, 2007

Specialty Excipients Used in Matrix Delivery Systems [US$ 3 600]

Table 8-1 LIST OF POLYMERS THAT CAN BE USED AS MATRIX FORMERS
Table 8-2 EXAMPLES OF DRUGS FORMULATED INTO A MATRIX SYSTEM FOR CONTROLLED RELEAS

Technology Trends [US$ 3 600]

Table 9-1 SELECTED DRIVERS CONTRIBUTING TO THE IMPROVEMENT OF EXCIPIENT TECHNOLOGY

Regulatory Issues [US$ 3 100]

Figure 10-1 SCHEMATIC OF THE ELABORATION OF MONOGRAPHS OF THE EP
Figure 10-2 SCHEMATIC OF THE ELABORATION OF MONOGRAPHS OF THE JP
Figure 10-3 SCHEMATIC OF THE ELABORATION OF MONOGRAPHS OF THE USP
Table 10-1 COMPARATIVE CHARACTERISTICS OF THE PDG HARMONIZATION PROCESS

Suppliers [US$ 7 800]

Table 11-1 ESTIMATED SALES VOLUME OF SPECIALTY BINDERS AND FILLERS, DISINTEGRANTS, AND LUBRICANTS FOR OSDF APPLICATIONS IN EUROPE BY SUPPLIER, 2007
Table 11-2 ESTIMATED SALES VALUE OF SPECIALTY BINDERS AND FILLERS, DISINTEGRANTS, AND LUBRICANTS FOR OSDF APPLICATIONS IN EUROPE BY SUPPLIER, 2007
Table 11-3 ESTIMATED SALES VALUE OF COATINGS FOR OSDF APPLICATIONS IN EUROPEBY SEGMENT AND SUPPLIER, 2007

Aqualon [US$ 900]

Table 11A-1 AQUALON’S SALES OF EXCIPIENTS FOR OSDF PHARMACEUTICAL APPLICATIONS IN EUROPE BY PRODUCT TYPE, 2007

Table 11A-2 AQUALON’S SALES OF EXCIPIENTS FOR OSDF PHARMACEUTICAL APPLICATIONS IN THE UNITED STATES BY PRODUCT TYPE, 2007

Table 11A-2 FORECAST SALES OF AQUALON’S EXCIPIENTS FOR OSDF PHARMACEUTICAL APPLICATIONS IN EUROPE BY PRODUCT TYPE, 2007 TO 2012

Table 11A-3 FORECAST SALES OF AQUALON’S EXCIPIENTS FOR OSDF PHARMACEUTICAL APPLICATIONS IN THE UNITED STATES BY PRODUCT TYPE, 2007 TO 2012

Cargill [US$ 900]

Table 11B-1 SELECTED SPECIALTY EXCIPIENTS MARKETED BY CARGILL, 2007

Table 11B-2 CARGILL’S SALES OF EXCIPIENTS FOR OSDF PHARMACEUTICAL APPLICATIONS IN EUROPE BY PRODUCT TYPE, 2007

Table 11B-3 CARGILL’S SALES OF EXCIPIENTS FOR OSDF PHARMACEUTICAL APPLICATIONS IN THE UNITED STATES BY PRODUCT TYPE, 2007

Table 11B-4 ESTIMATED SALES OF STARCHES FOR OSDF PHARMACEUTICAL APPLICATIONS IN EUROPE BY SUPPLIER AND PRODUCT TYPE, 2007

Colorcon [US$ 900]

Table 11C-1 LIST OF SELECTED PHARMACEUTICAL PRODUCTS AND TRADE NAMES OF COLORCON

Table 11C-2 COLORCON’S SALES OF EXCIPIENTS FOR OSDF PHARMACEUTICAL APPLICATIONS IN EUROPE BY PRODUCT TYPE, 2007

Table 11C-3 COLORCON’S SALES OF EXCIPIENTS FOR OSDF PHARMACEUTICAL APPLICATIONS IN THE UNITED STATES BY PRODUCT TYPE, 2007

Table 11C-4 ESTIMATED SALES OF DCS FOR OSDF PHARMACEUTICAL APPLICATIONS IN THE UNITED STATES BY SUPPLIER, 2007

Table 11C-5 FORECAST SALES OF COLORCON’S EXCIPIENTS FOR OSDF PHARMACEUTICAL APPLICATIONS IN EUROPE BY PRODUCT TYPE, 2007 TO 2012

Table 11C-6 FORECAST SALES OF COLORCON’S EXCIPIENTS FOR OSDF PHARMACEUTICAL APPLICATIONS IN THE UNITED STATES BY PRODUCT TYPE, 2007 TO 2012

DMV-Fonterra Excipients [US$ 900]

Table 11D-1 FORECAST SALES OF DFE’S EXCIPIENTS FOR OSDF PHARMACEUTICAL APPLICATIONS IN EUROPE BY PRODUCT TYPE, 2007 TO 2012

Table 11D-2 FORECAST SALES OF DFE’S EXCIPIENTS FOR OSDF PHARMACEUTICAL APPLICATIONS IN THE UNITED STATES BY PRODUCT TYPE, 2007 TO 2012

Dow Wolff Cellulosics [US$ 800]

Table 11E-1 DOW WOLFF CELLULOSICS’ SALES OF EXCIPIENTS FOR OSDF PHARMACEUTICAL APPLICATIONS IN EUROPE BY PRODUCT TYPE, 2007

Table 11E-2 DOW WOLFF CELLUOSICS’ SALES OF EXCIPIENTS FOR OSDF PHARMACEUTICAL APPLICATIONS IN THE UNITED STATES BY PRODUCT TYPE, 2007

Table 11E-3 SELECTED METHOCEL PRODUCTS MARKETED BY DOW CHEMICAL FOR PHARMACEUTICAL APPLICATIONS

Evonik Degussa [US$ 900]

Table 11F-1 SELECTED EVONIK PRODUCTS FOR OSDF APPLICATIONS, 2007

FMC Corp. [US$ 900]

Table 11G-1 FMC’S SALES OF EXCIPIENTS FOR OSDF PHARMACEUTICAL APPLICATIONS IN EUROPE BY PRODUCT TYPE, 2007

Table 11G-2 FMC’S SALES OF EXCIPIENTS FOR OSDF PHARMACEUTICAL APPLICATIONS IN THE UNITED STATES BY PRODUCT TYPE, 2007

Table 11G-3 FORECAST SALES OF FMC’S EXCIPIENTS FOR OSDF PHARMACEUTICAL APPLICATIONS IN EUROPE BY PRODUCT TYPE, 2007 TO 2012

Table 11G-4 FORECAST SALES OF FMC’S EXCIPIENTS FOR OSDF PHARMACEUTICAL APPLICATIONS IN THE UNITED STATES BY PRODUCT TYPE, 2007 TO 2012

International Specialty Products [US$ 900]

Table 11H-1 ISP’S SALES OF EXCIPIENTS FOR OSDF PHARMACEUTICAL APPLICATIONS IN EUROPE BY PRODUCT TYPE, 2007

Table 11H-2 ISP’S SALES OF EXCIPIENTS FOR OSDF PHARMACEUTICAL APPLICATIONS IN THE UNITED STATES BY PRODUCT TYPE, 2007

Table 11H-3 FORECAST SALES OF FMC’S EXCIPIENTS FOR OSDF PHARMACEUTICAL APPLICATIONS IN EUROPE BY PRODUCT TYPE, 2007 TO 2012

Table 11H-4 FORECAST SALES OF FMC’S EXCIPIENTS FOR OSDF PHARMACEUTICAL APPLICATIONS IN THE UNITED STATES BY PRODUCT TYPE, 2007 TO 2012

JRS Pharma [US$ 900]

Table 11I-1 LEADING EXCIPIENT PRODUCTS AND TRADE NAMES MARKETED TO PHARMACEUTICAL APPLICATIONS BY JRS, 2007

Table 11I-2 JRS’S SALES OF EXCIPIENTS FOR OSDF PHARMACEUTICAL APPLICATIONS IN EUROPE BY PRODUCT TYPE, 2007

Table 11I-3 JRS’S SALES OF EXCIPIENTS FOR OSDF PHARMACEUTICAL APPLICATIONS IN THE UNITED STATES BY PRODUCT TYPE, 2007

Table 11I-4 FORECAST SALES OF JRS’S EXCIPIENTS FOR OSDF PHARMACEUTICAL APPLICATIONS IN EUROPE BY PRODUCT TYPE, 2007 TO 2012

Table 11I-5 FORECAST SALES OF JRS’S EXCIPIENTS FOR OSDF PHARMACEUTICAL APPLICATIONS IN THE UNITED STATES BY PRODUCT TYPE, 2007 TO 2012

Roquette Frères [US$ 900]

Table 11J-1 LIST OF SELECTED EXCIPIENT PRODUCTS FROM ROQUETTE

Table 11J-2 ROQUETTE’S SALES OF EXCIPIENTS FOR OSDF PHARMACEUTICAL APPLICATIONS IN EUROPE BY PRODUCT TYPE, 2007

Table 11J-3 ROQUETTE’S SALES OF EXCIPIENTS FOR OSDF PHARMACEUTICAL APPLICATIONS IN THE UNITED STATES BY PRODUCT TYPE, 2007

Table 11J-4 ESTIMATED SALES OF POLYOLS FOR OSDF PHARMACEUTICAL APPLICATIONS IN THE UNITED STATES BY SUPPLIER, 2007

Table 11J-5 FORECAST SALES OF ROQUETTE’S EXCIPIENTS FOR OSDF PHARMACEUTICAL APPLICATIONS IN EUROPE BY PRODUCT TYPE, 2007 TO 2012

Table 11J-6 FORECAST SALES OF ROQUETTE’S EXCIPIENTS FOR OSDF PHARMACEUTICAL APPLICATIONS IN UNITED STATES BY PRODUCT TYPE, 2007 TO 2012

STEP 2 of 3

– Provide your contact information:

All fields in *BOLD are required.

*Name:
*Title:
*Company/Division:
*Address 1 :
Address 2 :
*City:
*State/Province:
*Zip/Postal code:
*Country:
*Phone:
Fax:
*Email:

STEP 3 of 3

– Review and accept our subscription terms and conditions by viewing and clicking below:

*Please view our terms and conditions, and check this box to indicate your acceptance of these terms and conditions.

Thank you for your interest in subscribing to our syndicated reports. To complete this process, please click on the button below and a member of our global sales team will contact you shortly to confirm the final price and complete the transaction. Upon acceptance of your order, we will deliver the files in PDF format via email.

Market Research: Specialty Excipients for Oral Solid-Dosage-Form Pharmaceuticals 2008: Europe Market Analysis and Opportunities

Specialty Excipients for Oral Solid-Dosage-Form Pharmaceuticals 2008: Europe Market Analysis and Opportunities

ORDER ONLINE

STEP 1 of 3

STEP 2 of 3

STEP 3 of 3

Questions?

Market Research: Specialty Excipients for Oral
Solid-Dosage-Form Pharmaceuticals 2008:
Europe Market Analysis and Opportunities